NCT06300411View on ClinicalTrials.gov

SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

SRG-514

SRG-514 monotherapy

Trial Locations (8)

10016

RECRUITING

NYU Langone Health, New York

27710

RECRUITING

Duke Cancer Center, Durham

31404

RECRUITING

Memorial Health, Savannah

46202

RECRUITING

Indiana University, Indianapolis

55905

RECRUITING

Mayo, Rochester

63110

RECRUITING

Washington University School of Medicine, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

Audie Murphy VA, San Antonio

Sponsors

Lead Sponsor

SURGE Therapeutics
All Listed Sponsors
lead

SURGE Therapeutics

INDUSTRY

NCT06300411 - SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | Biotech Hunter | Biotech Hunter